Docmode Health Technologies Ltd
Diversified Consumer Services | Small Cap
Docmode Health Technologies operates within the competitive Consumer Services sector, specifically Hospitality & Leisure. The company demonstrates a mixed financial performance. Strengths include solid solvency, driven by a healthy equity position and manageable debt levels, and robust efficiency in utilizing fixed assets and inventory. The company has also experienced good revenue and asset growth. Profitability metrics show positive returns on capital employed and equity, alongside a manageable operating margin. However, certain areas need attention, including liquidity, which is constrained by low current and cash ratios. Growth is hampered by negative trends in operating profit, EPS, and net income. Coverage ratios are weak, indicating challenges in covering interest and dividend obligations. Financial ratios are also mixed, with low book value per share and inconsistent earnings performance. Overall, Docmode Health Technologies shows potential but needs to address key financial weaknesses to ensure sustained success.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio4.80
- Financial Ratio4.80
- Profitability Ratio8.40
- Efficiency Ratio6.00
- Coverage Ratio3.20
- Solvency Ratio9.40
- Liquidity Ratio4.68
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Docmode Health Technologies operates within the competitive Consumer Services sector, specifically Hospitality & Leisure. The company demonstrates a mixed financial performance. Strengths include solid solvency, driven by a healthy equity position and manageable debt levels, and robust efficiency in utilizing fixed assets and inventory. The company has also experienced good revenue and asset growth. Profitability metrics show positive returns on capital employed and equity, alongside a manageable operating margin. However, certain areas need attention, including liquidity, which is constrained by low current and cash ratios. Growth is hampered by negative trends in operating profit, EPS, and net income. Coverage ratios are weak, indicating challenges in covering interest and dividend obligations. Financial ratios are also mixed, with low book value per share and inconsistent earnings performance. Overall, Docmode Health Technologies shows potential but needs to address key financial weaknesses to ensure sustained success.
Overall Valuation Score
P/E RATIO (TTM)
N/A
Industry Median
23.43
Small Cap Median
23.43
P/E RATIO
-6.90
P/B RATIO
1.68
Industry Median
1.98
Small Cap Median
1.98
P/S RATIO
0.33
Industry Median
2.99
Small Cap Median
2.99
Others
PEG RATIO
0.00
EV/EBITDA RATIO
52.42
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹44.6 as on Feb 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Growth ratios assess the rate at which a company expands. The company has experienced strong revenue and asset growth, reflecting business expansion. However, there are significant negative trends in operating profit, EPS, and net income growth, indicating potential challenges in profitability and earnings. Addressing these negative growth trends is crucial for sustained long-term success.
| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 2.31 | 74.93 | 164.73 | 21.44 | 4.46 |
| Operating Profit Growth Rate | 123.08 | 117.24 | 97.88 | -49.73 | -136.17 |
| Earnings Per Share (EPS) Growth | N/A | N/A | N/A | -92.94 | -1176.67 |
| Asset Growth Rate | 200 | 77.78 | 68.75 | 77.25 | 30.38 |
| Net Income Growth Rate | 61.76 | 67.27 | 111.96 | -90.26 | -1168.42 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial ratios provide insights into earnings and capital management. Adjusted and cash EPS are moderate but trending downward. Book value per share is low, indicating limited equity value. There are no dividends being paid. Capital expenditures are reasonably managed. Improving earnings and strengthening the balance sheet are key priorities.
| Financial Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 0 | 0 | 8.48 | 0.61 | -6.55 |
| Cash Earnings Per Share (Cash EPS) | 0 | 0 | 8.57 | 0.68 | -5.58 |
| Book Value Per Share | 0 | 0 | 15.09 | 33.45 | 26.94 |
| Dividend Per Share (DPS) | N/A | N/A | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 0 | 0.4 | 1.6 | 7.4 | 3.6 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability ratios measure the ability to generate earnings. The company demonstrates strong returns on capital employed and equity, alongside a reasonable operating margin. However, the gross profit margin is low, and the net margin is negative, indicating potential issues with cost management and overall profitability. Improving these margins is crucial for sustained financial health.
| Profitability Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Gross Profit Margin | 11.69 | 15.06 | 11.31 | 4.66 | -2.35 |
| Return on Capital Employed (ROCE) | 37.9 | 19.58 | 23.34 | 8.36 | -0.31 |
| Return on Equity (ROE) | 117.02 | 66.19 | 56.2 | 1.83 | -24.31 |
| Return on Assets (ROA) | 15.34 | 18.75 | 21.99 | 6.24 | -1.73 |
| Operating Margin | 12.25 | 15.22 | 11.37 | 4.71 | -1.63 |
| Net Margin | 7.75 | 7.41 | 5.93 | 0.48 | -4.87 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency ratios measure how well assets are utilized. The company shows strong efficiency in fixed asset turnover, indicating effective use of property and equipment. Inventory turnover is also reasonably good. However, receivable days are high, suggesting potential issues with collections. Capital turnover is relatively low, indicating room for improvement in utilizing capital. Overall, there are opportunities to optimize asset utilization for better financial performance.
| Efficiency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 44.38 | 24.84 | 15.88 | 41.16 | 34.19 |
| Inventory Turnover Ratio | 2.71 | 3.65 | 11.59 | 15.11 | 6.24 |
| Receivables Turnover Ratio | 10.36 | 4.8 | 5.43 | 4.04 | 4.03 |
| Days Sales in Inventory Ratio | 134.69 | 100 | 31.49 | 24.16 | 58.49 |
| Receivable Days | 35.23 | 76.04 | 67.22 | 90.35 | 90.57 |
| Capital Turnover Ratio | 3.24 | 1.29 | 2.01 | 1.67 | 2.56 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage ratios reflect the ability to cover financial obligations. Both the interest coverage ratio and the equity dividend coverage ratio are low, indicating potential difficulties in meeting interest and dividend commitments. Enhancing profitability and cash flow is essential for improving coverage ratios.
| Coverage Ratios | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Interest Coverage Ratio | 34 | 4.37 | 4.95 | 3.38 | 1.2 | -0.03 |
| Equity Dividend Coverage Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Solvency assesses the ability to meet long-term obligations. The company's solvency position is strong, with a low debt ratio and a healthy equity ratio. This indicates a solid financial structure and a good balance between debt and equity. The company's reliance on equity reduces financial risk and supports long-term financial stability. This strong solvency provides a solid foundation for future growth and stability.
| Solvency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debt Ratio | 0.58 | 0.71 | 0.56 | 0.3 | 0.12 |
| Debt to Equity Ratio | 1.38 | 2.45 | 1.27 | 0.43 | 0.14 |
| Equity Ratio | 0.42 | 0.29 | 0.44 | 0.7 | 0.88 |
| Debt To Asset Ratio | 0.12 | 0.33 | 0.26 | 0.15 | 0.03 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Liquidity indicates the ability to meet short-term obligations. The company's liquidity position is constrained. Current and cash ratios are low, raising concerns about immediate financial flexibility. While the quick ratio shows some ability to cover short-term liabilities with liquid assets, the overall scenario suggests that company might face difficulties in handling its immediate liabilities. Improving cash management and working capital efficiency is essential for better financial health.
| Liquidity Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Current Ratio | 1.19 | 1.57 | 1.51 | 1.26 | 0.84 |
| Quick Ratio | 0.47 | 1.1 | 1.23 | 1.1 | 0.47 |
| Cash Ratio | 0.07 | 0.03 | 0.04 | 0.2 | 0.06 |
| Operating Cash Flow Ratio | -0.11 | -0.39 | -0.09 | 0.29 | 0.22 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Usha Martin Education & Solutions Ltd | 6.65 | 54.00 | Overvalued | 0.44 | 0.14 | 0.39 |
| 2 | Docmode Health Technologies Ltd | 6.05 | -6.90 | Neutral | -0.68 | -6.46 | -2.03 |
| 3 | DSJ Keep Learning Ltd | 5.05 | -33.00 | Neutral | -0.76 | -0.06 | -0.97 |
| 4 | MT Educare Ltd | 3.93 | -2.41 | Neutral | -4.74 | -0.85 | -6.16 |
| 5 | Educomp Solutions Ltd | 3.47 | -0.35 | Highly Undervalued | -30.00 | -3.79 | -33.00 |
Docmode Health Technologies demonstrates a mixed performance. Strong revenue growth is offset by declining profitability and increasing financial leverage. Working capital management shows inefficiencies, requiring attention. Promoter holding remains stable. Overall, management effectiveness is mixed, necessitating careful monitoring.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (Mar 2020 - Mar 2024) | 50% CAGR | Strong revenue expansion |
| CONS | Net Profit (Mar 2023 - Mar 2025) | -2.03 Cr | Recent loss indicates challenges in profitability |
| CONS | ROCE (Mar 2021 - Mar 2025) | -0.29% | Declining returns on capital employed |
Financial Performance & Growth
Docmode Health Technologies has shown inconsistent financial performance. Sales growth has been robust, but profitability has declined recently. The company's ability to convert revenue growth into sustainable profits is questionable.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales (₹ Cr) | 6.94 | 7.10 | 12.42 | 32.88 | 39.93 | 41.77 |
| Sales Growth (%) | 2.31% | 74.93% | 164.73% | 21.44% | 4.61% | |
| Net Profit (₹ Cr) | 0.34 | 0.55 | 0.92 | 1.95 | 0.19 | -2.03 |
Capital Efficiency & Returns
The company's capital efficiency and returns are weak. ROCE has declined significantly, turning negative in the most recent year. ROE has also decreased, indicating inadequate returns from shareholder funds.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| ROCE (%) | 113.70% | 48.45% | 42.02% | 12.70% | -0.29% |
| ROE (%) | -22% |
Financial Health & Prudence
Docmode Health Technologies faces challenges in its financial health as borrowings have increased. Dividend payments have been nil.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Borrowings (₹ Cr) | 0.02 | 1.06 | 4.84 | 8.48 | 9.18 | 6.82 |
| Dividend Payout (%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Strategic & Operational Indicators
Docmode Health Technologies shows mixed strategic and operational performance. Debtor days and inventory days are fluctuating, indicating potential inefficiencies in working capital management.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 0.53 | 69.92 | 112.26 | 92.03 | 72.31 | 80.74 |
| Inventory Days | 120.77 | 668.83 | 501.37 | 315.91 | 112.91 |
Docmode Health Technologies presents a moderate risk profile characterized by strengths in sales growth offset by declining profitability and increasing financial leverage. Working capital management inefficiencies and significant changes in inventory levels raise concerns. These factors indicate a need for vigilant risk monitoring.
Off-balance sheet exposure quantification
Other Liabilities have increased significantly from 6.85 Cr(Mar 2024) to 24.14 Cr(Mar 2025). It indicates an increase in off-balance sheet exposure quantification.
Segment performance volatility
The company exhibits volatility in its quarterly sales and operating profit margin (OPM). Sales have fluctuated, and the OPM has moved from positive to negative values, indicating inconsistent operational performance.
Foreign exchange or interest rate exposure
The company's interest expenses have been increasing steadily, from ₹0.01 Cr in Mar 2020 to ₹1.92 Cr in Mar 2025. This rise in interest expenses indicates a growing exposure to interest rate fluctuations.
Regulatory compliance cost trends
Other Cost increased from 75%(Mar 2024) to 6%(Mar 2025). It indicates an increase in Regulatory compliance cost trends.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe